Attendee search 

Learn more.

We provide life cycle management solutions for innovator and branded pharmaceutical, medical device, biological products manufacturers. This entails winning difficult-to-obtain patents, designing Intellectual Property strategy and enforcing intellectual property to maintain market share.

I will shortly begin to interview companies able to register and launch a new US Rx product outside the US.  Partner companies must have (a) a women's health or rheumatology sales force; (b) experience registering hormone products; and (c) the ability to move quickly. 

From helping Tenet Healthcare stave off a hostile takeover to obtaining summary judgment for a former health care general counsel in a precedent-setting False Claims Act case to establishing ERISA preemption precedent in the United States Supreme Court on behalf of Aetna, achieving successful outcomes for our clients in their most important matters is our singular focus.

Provid Pharmaceuticals Inc. was founded to discover novel therapeutics for autoimmune diseases using peptide mimetics technology.   Provid’s strategy has resulted in the discovery of PV-267, a small molecule drug candidate for the treatment of multiple sclerosis (MS) and leads for rheumatoid arthritis and other autoimmune diseases that operate by blocking disease-associated MHC class II molecules.

Provid’s MS drug candidate, PV-267 uniquely inhibits the MHC Class II molecule HLA-DR2b, the most important gene target in the autoimmune disease process in MS.  MS is genetically linked with HLA-DR2b (DRB1*1501).  DR2b is carried by a majority of MS patients (ca. 700,000 worldwide) and binds and presents antigenic myelin fragments to autoreactive T cells, triggering the autoimmune response that damages myelin insulation on nerves, leading to MS disease symptoms and disability.  Provid designed PV-267 to bind tightly and selectively to DR2b, blocking antigen binding.  PV-267 has been shown to disrupt the autoimmune process in MS animal models and in human cells from DR2+ patients.  Because PV-267 does not compromise other aspects of the immune system, its potential for superior safety is a major advantage over current disease-modifying drugs.

Recent data have shown that PV-267 has high oral bioavailability in a proprietary formulation being developed in collaboration with Enteris Biopharma.  Oral efficacy, while not essential to test the concept of the DR2 inhibitory mechanism, is an important factor commercially and for the MS patient.

Early Clinical Trial Concept.  Because of its DR2b antagonist mechanism, it is feasible to assess immunological efficacy in DR2b+ individuals in early clinical trials, greatly reducing the clinical development risk and clearing the path for a targeted phase II efficacy trial.  These studies are being planned by our Clinical Advisory Board under the leadership of Prof. Larry Steinman at Stanford. 

Development Plan. Provid will pursue preclinical and early clinical studies of our DR2b inhibitors and is seeking partnerships with pharma company partners.

Founded in 1853 in Hartford, CT, Aetna is committed to providing individuals, employers, health care professionals, producers and others with innovative benefits, products and services. Discover more about our organization.

In 2008 the Leducq Family Trust established Broadview Ventures, Inc.(Broadview). Broadview’s mission is to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures.

By making funding available at a critical moment in the development of new technology, the Leducq Family Trust is taking a leadership position in venture philanthropy by finding creative ways to support translational research in order to bring the advancements of science to the care of patients.

Nishant "Nish" Rastogi shares responsibility for the day-to-day operations of Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement.

UMass Amherst, the Commonwealth's flagship campus, is a nationally ranked public research university offering a full range of undergraduate, graduate and professional degrees.

NYU Langone Medical Center is one of the nation’s premier academic medical centers. Our trifold mission to serve, teach, and discover is achieved daily through an integrated academic culture devoted to excellence in patient care, education, and research.

Located in the heart of Manhattan, with additional facilities throughout the New York City area, NYU Langone consists of four hospitals:

• Tisch Hospital, our flagship acute-care facility
• Rusk Rehabilitation, ranked as one of the top 10 rehabilitation programs in the country by U.S. News & World Report since 1989, and recently awarded a three-year accreditation from the Commission on Accreditation of Rehabilitation Facilities  (CARF)
• Hospital for Joint Diseases, a dedicated inpatient orthopaedic hospital 
• Hassenfeld Children’s Hospital, which provides comprehensive children's health services across NYU Langone